News Article | December 2, 2016
According to Stratistics MRC, the Global Veterinary Healthcare market is accounted for $24.34 billion in 2015 and is expected to reach $40.8 billion by 2022 growing at a CAGR of 7.6% from 2015 to 2022. Factors such as food safety and improved nutrition, increase in pet ownership, increasing awareness of zoonotic diseases and increasing animal population are driving the market. However, increasing cost of animal testing, increased competition for cultivated land restrictions established by regulatory bodies will challenge the veterinary market. Feed additives held the largest share among the products segment followed by pharmaceuticals and vaccines. Europe is the leading market in veterinary healthcare followed by North America. Asia-pacific and other developing regions will be the major contributors to the market. Some of the key players in global Veterinary Healthcare market are Merck & Co., Inc, MERIAL Limited, Zoetis Inc, Novartis Animal Health Inc, Bayer HealthCare, Ceva Santé Animale, Boehringer Ingelheim GmbH, Virbac SA, Elanco Products Company, Vétoquinol SA, Sanofi-Aventis, Intas Pharmaceuticals Ltd., Heska Corporation, PetAg Incorporated and Procter & Gamble Company. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements
News Article | February 15, 2017
Sarasota, FL, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Male Infertility Treatment Market by Techniques (DNA fragmentation, Oxidative stress analysis, Sperm penetration, Microscopic analysis, Sperm agglutination and Others) - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2014 – 2022”. According to the report, the global male infertility treatment market accounted for USD 248.3 million in 2016 and is expected to reach USD 334.6 by 2022, growing at a CAGR of around 5.1% between 2017 and 2022. According to Word Health Organization, ‘Infertility is the inability of a sexually active, non-contraception couple to achieve pregnancy in one year’. About 15% of couples do not achieve pregnancy within 1year and seeking for infertility medical treatment. Less than 5% of world population is unwillingly childless. Approximately 90% of male infertility cases are seen mainly due to low sperm counts, and poor sperm quality. The remaining cases of male infertility can be caused by a number of factors including anatomical problems, hormonal imbalances, and genetic defects. Browse through 16 Market Tables and 28 Figures spread through 167 Pages and in-depth TOC on “Global Male Infertility Treatment Market: By Techniques Type, Size, Share, Trends, Analysis, Segment and Forecast 2016 – 2022”. Male infertility treatment market is driven mainly by increasing incidence of male infertility cases across the different part of the world. For instance, According to the WHO, 1 in every 4 couples in developing countries is expected to be affected by infertility. Moreover, the couples who are not able to have a child are failed to opt for the expensive treatment options for fulfilling their desires which lead to the growth of male infertility market. In addition, torpid lifestyle, increasing age and various environmental and psychological effects are the factors which are directly responsible for increasing growth of male infertility market. However, due to emotional shock and discontinuation of treatment is the key limitation which directly affects the growth of male infertility treatment market. Nonetheless, low-cost treatment and continuous ongoing research and development in the healthcare sector are expected to open growth avenues for the market over the years. Based on techniques, the global market for male infertility treatment is bifurcated into five types: DNA fragmentation, Oxidative stress analysis, Sperm penetration, Microscopic analysis, Sperm agglutination and others. DNA fragmentation dominated the male infertility treatment market. The growth of this technique is attributed due to its highest accuracy followed by others. Browse the full "Male Infertility Treatment Market by Techniques (DNA fragmentation, Oxidative stress analysis, Sperm penetration, Microscopic analysis, Sperm agglutination and Others) - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2014 – 2022" report at https://www.zionmarketresearch.com/report/male-infertility-treatment-techniques-market Based on regions, North America is the dominating segment in male infertility treatment market. This growth is attributed majorly because of certain factors which include, raising awareness, high-end technological advancements, lifestyle factors such as diet and obesity. Higher healthcare expenditure and encouraging healthcare infrastructure in the U.S. are major growth factors for male infertility treatment market in this region. In addition, high literacy rate coupled with the increase in a number of health care centers are likely to drive the male infertility treatment market. Europe was the second largest market for global male infertility treatment market in 2016. The Central and Eastern Europe contributed approximately 8-12% of total cases of male infertile populations. This growth is mainly associated with rising stress level, obesity, and torpid lifestyle. Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/male-infertility-treatment-techniques-market Asia Pacific is expected to be the fastest growing regional segment for male infertility treatment market within the forecast period. This growth is attributed primarily due to the introduction of newer techniques in the treatment of male infertility such as computer assisted semen analysis and DNA fragmentation. In addition, rising infertility cases and awareness about infertility treatment are also considered as a major driving factor for the growth of Asia Pacific market. The government encourages the adoption of the technological advancements but uncertain returning policy by insurance companies for infertility treatment can limit the people to go for the treatment. The growing medical sector and literacy rate mainly in China, Japan, India, Indonesia, Philippines, and Thailand are expected to be the major driver of the market. In addition, rising awareness towards benefits of medical treatment in emerging economies of China and India is expected to augment the market growth of male infertility treatments. Key players of male infertility treatment market included in the report are ASKA Pharmaceutical Co. Ltd, ZydusCadila Healthcare Limited, Access Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Pantarhei Bioscience B, Cordex Pharma, Inc., Merck Serono, Halotech DNA SL, SCSA diagnostics, Andrology Solutions. For more inquiry contact our sales team @ firstname.lastname@example.org This report segments the male infertility treatment market are follows: Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
INTAS PHARMACEUTICALS Ltd | Date: 2013-10-11
The present invention relates to an improved process for the preparation of Fulvestrant (I). Also, provided is novel intermediate of Fulvestrant and a process for the preparation of the same.
Intas Pharmaceuticals Ltd | Date: 2014-04-28
A polynucleotide sequence and a method for Ranibizumab cloning, expression and production having better yield and biologically active protein.
INTAS PHARMACEUTICALS Ltd | Date: 2015-02-23
The present invention relates to a stable transdermal gel composition comprising Testosterone, a penetration enhancer, a gelling agent with pharmaceutically acceptable excipients. Further, the invention relates to the method of administering the said transdermal gel and its uses thereof.
INTAS PHARMACEUTICALS Ltd | Date: 2011-05-10
A process for the preparation of phenolic monoesters of 2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol by converting ()6-halo-4-phenylchroman-2-one to ()4-halo-2-(3-hydroxy-1-phenylpropyl)phenol. The two hydroxyl groups are protected and the protected compound is reacted with diisopropylamine to give ()[3-(2-benzyloxy-5-halophenyl)-3-phenylpropyl]diisopropylamine. The halo substituent on the benzene ring is converted to corresponding benzyl alcohol and then the protection is removed to give racemic 5-HMT. Racemic 5-HMT is converted R enantiomer and then it is esterified.
INTAS PHARMACEUTICALS Ltd | Date: 2010-10-25
A method of preparing O-desmethylvenlafaxine from Venlafaxine or its pharmaceutically acceptable salt is disclosed. The disclosed method involves the use of mercapto carboxylic acids in the presence of suitable solvents under alkaline conditions. The disclosed process provides a novel and industrially feasible process for the preparation of O-desmethylvenlafaxine. The disclosed process also provides a cost effective, non-hazardous and efficient process for preparing O-desmethylvenlafaxine.
INTAS PHARMACEUTICALS Ltd | Date: 2014-09-29
A pharmaceutical compositions having fixed dose combinations of capecitabine and cyclophosphamide, processes for the preparation thereof, and their use to treat cancer diseases.
INTAS PHARMACEUTICALS Ltd | Date: 2013-10-31
The present invention relates to a novel process for preparation of cabazitaxel (I) starting from 10-Deacetyl baccatin or derivative that involves methylation of 7, 10 OH groups. Also provided is a novel process using chiral bis-lactam linker for the synthesis of cabazitaxel.
Intas Pharmaceuticals Ltd. | Date: 2011-01-24
This disclosure relates to a crystalline form of O-desmethylvenlafaxine and a process for its preparation. The disclosed crystalline form of O-desmethylvenlafaxine can be used for the manufacture of pharmaceutical compositions for the treatment of depression.